The safety of gliptins : updated data in 2018

Expert Opinion on Drug Safety
André J Scheen

Abstract

Dipeptidyl peptidase-4 inhibitors (DPP-4is) are generally considered as glucose-lowering agents with a safe profile in type 2 diabetes. Areas covered: An updated review of recent safety data from randomised controlled trials, observational studies, meta-analyses, pharmacovigilance reports regarding alogliptin, linagliptin, saxagliptin, sitagliptin, and vildagliptin, with a special focus on risks of hypoglycemia, pancreatitis and pancreatic cancer, major cardiovascular events, hospitalisation for heart failure and other new safety issues, such as bone fractures and arthralgia. The safety of DPP-4i use in special populations, elderly patients, patients with renal impairment, liver disease or heart failure, will also be discussed. Expert opinion: The good tolerance/safety profile of DPP-4is has been largely confirmed, including in more fragile populations, with no gastrointestinal adverse effects and a minimal risk of hypoglycemia. DPP-4is appear to be associated with a small increased incidence of acute pancreatitis in placebo-controlled trials, although most observational studies are reassuring. Most recent studies with DPP-4is do not confirm the increased risk of hospitalisation for heart failure reported with saxagliptin in SA...Continue Reading

References

Jul 2, 2010·Diabetes, Obesity & Metabolism·A J Scheen
Feb 22, 2011·Gastroenterology·Michael ElashoffPeter C Butler
Nov 11, 2011·Clinical Therapeutics·Kathleen R RichardJulienne K Kirk
Dec 14, 2011·Expert Opinion on Pharmacotherapy·André J Scheen
Mar 14, 2012·Advances in Therapy·Giuseppe PaolissoEdoardo Mannucci
Jan 9, 2013·Nature Reviews. Cardiology·André J Scheen
Mar 2, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Julio RosenstockHans-Jürgen Woerle
Apr 30, 2013·Expert Opinion on Drug Safety·Andre Scheen
Aug 14, 2013·Diabetes Research and Clinical Practice·Tatsuhiko SaitoChikao Morimoto
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Feb 28, 2014·The New England Journal of Medicine·Amy G EganCurtis Rosebraugh
Apr 2, 2014·European Journal of Heart Failure·Henry KrumIngrid Hopper
May 24, 2014·Circulation Research·John R Ussher, Daniel J Drucker
May 27, 2014·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Hsin-Chun ChouFei-Yuan Hsiao
Aug 2, 2014·Therapeutic Advances in Drug Safety·Thomas KaragiannisApostolos Tsapas
Aug 30, 2014·Expert Opinion on Drug Safety·Antonio CerielloFrancesco Rossi
Sep 13, 2014·Endocrine Reviews·Erin E Mulvihill, Daniel J Drucker
Oct 7, 2014·Current Treatment Options in Cardiovascular Medicine·Eberhard StandlOliver Schnell
Oct 23, 2014·Clinical Pharmacokinetics·Elizabeth BarbehennSidney Wolfe
Oct 23, 2014·Clinical Pharmacokinetics·André J Scheen
Nov 11, 2014·Expert Opinion on Pharmacotherapy·André J Scheen
Dec 10, 2014·Expert Opinion on Drug Safety·Sri Harsha Tella, Marc S Rendell
Dec 17, 2014·International Journal of Cardiology·Kang-Ling WangChern-En Chiang
Jan 30, 2015·Expert Opinion on Drug Safety·André J Scheen
Jan 31, 2015·Diabetes Care·Reimar Wernich ThomsenHenrik Toft Sørensen
Feb 11, 2015·The Journal of Clinical Endocrinology and Metabolism·Mavin MacauleyRoy Taylor
Feb 26, 2015·Diabetes, Obesity & Metabolism·A S AbdelmoneimS H Simpson
Mar 12, 2015·Diabetes Care·Lawrence A LeiterUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators

❮ Previous
Next ❯

Citations

Oct 10, 2018·Expert Opinion on Pharmacotherapy·Emanuel RaschiGiulio Marchesini
Nov 24, 2018·Diabetes/metabolism Research and Reviews·Evangelia KalaitzoglouKathryn M Thrailkill
Jan 24, 2019·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Maryam RameshradHossein Hosseinzadeh
May 20, 2020·Diabetic Medicine : a Journal of the British Diabetic Association·R D Carr, A Solomon
Sep 30, 2020·Expert Opinion on Pharmacotherapy·Kazuki Orime, Yasuo Terauchi
Oct 28, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kohei KakuTakashi Oohira
Jan 4, 2019·Acta Diabetologica·Giorgio SestiFrancesco Purrello
Aug 30, 2019·Pharmacoepidemiology and Drug Safety·Matthew H SecrestKristian B Filion
Sep 16, 2020·Nature Reviews. Endocrinology·Carolyn F Deacon
May 14, 2019·Frontiers in Endocrinology·Jens Juul Holst
Apr 2, 2019·Expert Opinion on Drug Safety·André J Scheen
Jul 6, 2019·Frontiers in Endocrinology·Baptist Gallwitz
Jun 4, 2020·European Journal of Clinical Pharmacology·Keisuke TadaMasahiko Gosho
Aug 11, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Pravesh Kumar Bundhun, Feng Huang
Feb 28, 2020·BioMed Research International·Huimin HouYanli Cao
Nov 10, 2020·AACE Clinical Case Reports·Jorge Esteban MosqueraSowmya Suryanarayanan
Nov 30, 2020·Diabetes & Metabolism·André J Scheen
Apr 4, 2021·Medicina·Claudio PonticelliMariano Ferraresso
Mar 30, 2021·Frontiers in Pharmacology·Felix F LillichEwgenij Proschak
Apr 8, 2021·Expert Opinion on Pharmacotherapy·André J Scheen
Jul 27, 2021·International Journal of Clinical Practice·Marwa MohsenRaghda R S Hussein
Dec 8, 2021·Clinical and Molecular Allergy : CMA·Nicoletta CassanoCaterina Foti

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.